A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma
Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang · 2026
Read A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma by Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13269839.txt.
Description
Mingming Hu and co-authors published a trial report in 2026 on immune therapy plus chemotherapy around surgery for stage IIB to IIIB lung squamous cell cancer. Patients got two cycles of the immune drug camrelizumab with two chemotherapy drugs before surgery. The immune drug then continued for a year after surgery.
Forty-five patients were treated, and 41 reached surgery. Sixty percent achieved a major tumor response in the removed tissue, and 44.4 percent had no cancer left in it. At three years, 65.9 percent were disease-free and 68.7 percent were alive. Blood measures and smoking history were linked to major response. Certain immune cell gene patterns also differed between full and partial responders. The authors back the combined approach.
Catalog record
| CREATOR | Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49577 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |